title: Improved results of lung transplantation for patients with cystic fibrosis.
abstract: Patients with cystic fibrosis pose particular challenges for lung transplant surgeons. Earlier reports from North American centers suggested that patients with cystic fibrosis were at greater risk for heart-lung or isolated lung transplantation than other patients with end-stage pulmonary disease. During a 3 1/2 year period, 44 patients with end-stage lung disease resulting from cystic fibrosis underwent double lung transplantation at this institution. During the same interval, 18 patients with cystic fibrosis died while waiting for lung transplantation. The ages of the recipients ranged from 8 to 45 years, and mean forced expiratory volume in 1 second was 21% predicted. Seven patients had Pseudomonas cepacia bacteria before transplantation. Bilateral sequential implantation with omentopexy was used in all patients. There were no operative deaths, although two patients required urgent retransplantation because of graft failure. Cardiopulmonary bypass was necessary in six procedures in five patients and was associated with an increased blood transfusion requirement, longer postoperative ventilation, and longer hospital stay. Actuarial survival was 85% at 1 year and 67% at 2 years. Infection was the most common cause of death within 6 months of transplantation (Pseudomonas cepacia pneumonia was the cause of death in two patients), and bronchiolitis obliterans was the most common cause of death after 6 months. Actuarial freedom from development of clinically significant bronchiolitis obliterans was 59% at 2 years. Results of pulmonary function tests improved substantially in survivors, with forced expiratory volume in 1 second averaging 78% predicted 2 years after transplantation. Double lung transplantation can be accomplished with acceptable morbidity and mortality in patients with cystic fibrosis.
authors.affiliation: Division of Cardiothoracic Surgery (Department of Surgery), University of North Carolina at Chapel Hill.
authors.forename: T M
authors.initials: TM
authors.lastname: Egan
authors.forename: F C
authors.initials: FC
authors.lastname: Detterbeck
authors.forename: M R
authors.initials: MR
authors.lastname: Mill
authors.forename: L J
authors.initials: LJ
authors.lastname: Paradowski
authors.forename: R P
authors.initials: RP
authors.lastname: Lackner
authors.forename: W D
authors.initials: WD
authors.lastname: Ogden
authors.forename: J R
authors.initials: JR
authors.lastname: Yankaskas
authors.forename: J H
authors.initials: JH
authors.lastname: Westerman
authors.forename: J T
authors.initials: JT
authors.lastname: Thompson
authors.forename: M A
authors.initials: MA
authors.lastname: Weiner
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D001989:Bronchiolitis Obliterans / Q000401:mortality; D016956:Burkholderia cepacia; D002315:Cardiopulmonary Bypass; D002423:Cause of Death; D003550:Cystic Fibrosis / Q000401:mortality / Q000601:surgery*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D016040:Lung Transplantation / Q000379:methods / Q000401:mortality; D008297:Male; D018410:Pneumonia, Bacterial / Q000382:microbiology / Q000401:mortality; D011183:Postoperative Complications / Q000453:epidemiology* / Q000401:mortality; D012086:Reoperation; D012129:Respiratory Function Tests; D012307:Risk Factors; D013997:Time Factors